Cargando…

Liver Effects of Clinical Drugs Differentiated in Human Liver Slices

Drugs with clinical adverse effects are compared in an ex vivo 3-dimensional multi-cellular human liver slice model. Functional markers of oxidative stress and mitochondrial function, glutathione GSH and ATP levels, were affected by acetaminophen (APAP, 1 mM), diclofenac (DCF, 1 mM) and etomoxir (ET...

Descripción completa

Detalles Bibliográficos
Autores principales: Vickers, Alison E. M., Ulyanov, Anatoly V., Fisher, Robyn L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372590/
https://www.ncbi.nlm.nih.gov/pubmed/28272341
http://dx.doi.org/10.3390/ijms18030574
_version_ 1782518650377338880
author Vickers, Alison E. M.
Ulyanov, Anatoly V.
Fisher, Robyn L.
author_facet Vickers, Alison E. M.
Ulyanov, Anatoly V.
Fisher, Robyn L.
author_sort Vickers, Alison E. M.
collection PubMed
description Drugs with clinical adverse effects are compared in an ex vivo 3-dimensional multi-cellular human liver slice model. Functional markers of oxidative stress and mitochondrial function, glutathione GSH and ATP levels, were affected by acetaminophen (APAP, 1 mM), diclofenac (DCF, 1 mM) and etomoxir (ETM, 100 μM). Drugs targeting mitochondria more than GSH were dantrolene (DTL, 10 μM) and cyclosporin A (CSA, 10 μM), while GSH was affected more than ATP by methimazole (MMI, 500 μM), terbinafine (TBF, 100 μM), and carbamazepine (CBZ 100 μM). Oxidative stress genes were affected by TBF (18%), CBZ, APAP, and ETM (12%–11%), and mitochondrial genes were altered by CBZ, APAP, MMI, and ETM (8%–6%). Apoptosis genes were affected by DCF (14%), while apoptosis plus necrosis were altered by APAP and ETM (15%). Activation of oxidative stress, mitochondrial energy, heat shock, ER stress, apoptosis, necrosis, DNA damage, immune and inflammation genes ranked CSA (75%), ETM (66%), DCF, TBF, MMI (61%–60%), APAP, CBZ (57%–56%), and DTL (48%). Gene changes in fatty acid metabolism, cholestasis, immune and inflammation were affected by DTL (51%), CBZ and ETM (44%–43%), APAP and DCF (40%–38%), MMI, TBF and CSA (37%–35%). This model advances multiple dosing in a human ex vivo model, plus functional markers and gene profile markers of drug induced human liver side-effects.
format Online
Article
Text
id pubmed-5372590
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53725902017-04-10 Liver Effects of Clinical Drugs Differentiated in Human Liver Slices Vickers, Alison E. M. Ulyanov, Anatoly V. Fisher, Robyn L. Int J Mol Sci Article Drugs with clinical adverse effects are compared in an ex vivo 3-dimensional multi-cellular human liver slice model. Functional markers of oxidative stress and mitochondrial function, glutathione GSH and ATP levels, were affected by acetaminophen (APAP, 1 mM), diclofenac (DCF, 1 mM) and etomoxir (ETM, 100 μM). Drugs targeting mitochondria more than GSH were dantrolene (DTL, 10 μM) and cyclosporin A (CSA, 10 μM), while GSH was affected more than ATP by methimazole (MMI, 500 μM), terbinafine (TBF, 100 μM), and carbamazepine (CBZ 100 μM). Oxidative stress genes were affected by TBF (18%), CBZ, APAP, and ETM (12%–11%), and mitochondrial genes were altered by CBZ, APAP, MMI, and ETM (8%–6%). Apoptosis genes were affected by DCF (14%), while apoptosis plus necrosis were altered by APAP and ETM (15%). Activation of oxidative stress, mitochondrial energy, heat shock, ER stress, apoptosis, necrosis, DNA damage, immune and inflammation genes ranked CSA (75%), ETM (66%), DCF, TBF, MMI (61%–60%), APAP, CBZ (57%–56%), and DTL (48%). Gene changes in fatty acid metabolism, cholestasis, immune and inflammation were affected by DTL (51%), CBZ and ETM (44%–43%), APAP and DCF (40%–38%), MMI, TBF and CSA (37%–35%). This model advances multiple dosing in a human ex vivo model, plus functional markers and gene profile markers of drug induced human liver side-effects. MDPI 2017-03-07 /pmc/articles/PMC5372590/ /pubmed/28272341 http://dx.doi.org/10.3390/ijms18030574 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vickers, Alison E. M.
Ulyanov, Anatoly V.
Fisher, Robyn L.
Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
title Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
title_full Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
title_fullStr Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
title_full_unstemmed Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
title_short Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
title_sort liver effects of clinical drugs differentiated in human liver slices
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372590/
https://www.ncbi.nlm.nih.gov/pubmed/28272341
http://dx.doi.org/10.3390/ijms18030574
work_keys_str_mv AT vickersalisonem livereffectsofclinicaldrugsdifferentiatedinhumanliverslices
AT ulyanovanatolyv livereffectsofclinicaldrugsdifferentiatedinhumanliverslices
AT fisherrobynl livereffectsofclinicaldrugsdifferentiatedinhumanliverslices